Back to News
Market Impact: 0.18
Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Breye Therapeutics announced publication of a paper on danegaptide, its lead asset, in Science Translational Medicine. The peer-reviewed publication provides scientific validation for the program, but the announcement includes no clinical efficacy data, regulatory milestone, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- China's AI chip blitz arms Xi with a message for Trump: 'You can't choke us off'
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Chinese authorities reportedly in possession of F-35 components in Hong Kong
- Australia says OpenAI agent hacked Medicare portal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle
- AI Research Tools With Exact Source Citations